Cost-effectiveness analysis results using institutional costs and AWP
| Institutional cost . | AWP . | |||||||
|---|---|---|---|---|---|---|---|---|
| Primary base-case analysis . | PSA . | Secondary base-case analysis . | PSA . | |||||
| Drug . | Cost, $ . | AEA . | Cost, $ . | AEA . | Cost, $ . | AEA . | Cost, $ . | AEA . |
| Argatroban | 1250 | 0.9957 | 1186 | 0.9957 | 3081 | 0.9957 | 3017 | 0.9958 |
| Bivalirudin | 1466 | 0.9947 | 1400 | 0.9947 | 2187 | 0.9947 | 2121 | 0.9948 |
| Fondaparinux | 151 | 0.9989 | 151 | 0.9989 | 555 | 0.9989 | 555 | 0.9989 |
| Institutional cost . | AWP . | |||||||
|---|---|---|---|---|---|---|---|---|
| Primary base-case analysis . | PSA . | Secondary base-case analysis . | PSA . | |||||
| Drug . | Cost, $ . | AEA . | Cost, $ . | AEA . | Cost, $ . | AEA . | Cost, $ . | AEA . |
| Argatroban | 1250 | 0.9957 | 1186 | 0.9957 | 3081 | 0.9957 | 3017 | 0.9958 |
| Bivalirudin | 1466 | 0.9947 | 1400 | 0.9947 | 2187 | 0.9947 | 2121 | 0.9948 |
| Fondaparinux | 151 | 0.9989 | 151 | 0.9989 | 555 | 0.9989 | 555 | 0.9989 |
AEA, adverse event averted.